Establishment of various biliary tract carcinoma cell lines and xenograft models for appropriate preclinical studies

Table 2 Sensitivity to gemcitabine in each cell line

Cell line	Sensitivity to gemcitabine in cell line1
	IC50 (μmol/L)	IC60 (μmol/L)	IC70 (μmol/L)	IC80 (μmol/L)
NCC-CC1	86.78	N.A	N.A	N.A
NCC-CC3-1	0.04	1.82	9.31	85.21
NCC-CC3-2	0.10	1.92	43.83	N.A
NCC-CC4-1	0.05	4.08	N.A	N.A
NCC-CC4-2	0.03	11.53	N.A	N.A
NCC-CC4-3 (NCC-CC5)	0.06	4.92	95.10	N.A
NCC-CC6-1	0.01	0.02	0.06	3.76
NCC-CC6-2	10.98	35.67	N.A	N.A
NCC-BD1	7.66	58.00	N.A	N.A
NCC-BD2	N.A	N.A	N.A	N.A
NCC-BD3	N.A	N.A	N.A	N.A
NCC-BD4-1	0.04	0.06	0.09	2.93
NCC-BD4-2	0.06	0.07	0.19	5.37

¹The cytotoxicity of gemcitabine for each cell line was assessed by a modified 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt assay with CellTiter 96 Aqueous One Solution Reagent (Promega, Madison, WI, United States). Tumor cells (3000 cells⁄well) in the exponential growth phase were grown in 96-well plates. IC: Inhibitory concentration.